in Gene Therapy
We are accelerating the development of transformative gene therapies, aiming to enhance the quality of lives of patients with severe and life-threatening diseases.
From bench to bedside, as rapidly as possible
Through the development of innovative gene therapies, our goal is to confront these life-threatening diseases head-on, targeting faulty genes and introducing functional genetic material to restore function.Our team is working tirelessly to accelerate the success of transformational therapeutic programs – from bench to bedside.
The need is urgent
All over the world there are patients, families, and physicians in critical need of a disease-modifying treatment for devastating, genetically-defined diseases. Too often they are faced with the horrible truth that nothing can be done; there are no options.
Jaguar: Uniquely positioned to bring new gene therapy products to patients
Our team is led by alumni of gene therapy pioneer, AveXis, and backed by Deerfield Management Company. By putting the right expertise in the right area at the right time, we can develop and bring novel treatments to market for patients suffering from rare and life-threatening genetic diseases.
- Experienced and proven management team
- Scalable GMP gene therapy development know-how: broad capabilities with deep manufacturing, quality, clinical and commercial expertise
- Access to capital, significant resources and experience of Deerfield
News and Updates
The pioneering collaboration completed the licensing of the first Apollo-supported project, a novel gene therapy programme developed at University College London (UCL)
$635 Million in Real Estate and Multi-Disciplinary Laboratory Infrastructure Will Combine With Multi-Billion Dollar Investments in Research to Transform the Battle Against Disease